PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S.

PRESS RELEASE July 14 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ( $10 million ) with Formue Nord Fokus A/S.

PRESS RELEASE June 30 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a P hase 1 clinical trial of SAN711, a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine.

PRESS RELEASE June 29 , 2021 Today, on June 29 , 2021 , an extraordinary shareholders’ meeting was held in Saniona AB . In light of the ongoing Covid -19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with

PRESS RELEASE June 25 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its partner Productos Medix , S.A de S.V, (Medix) has provided Saniona with an update on the Mexican regulatory authority Comisión Federal para la Protección

PRESS RELEASE June 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it will present preclinical data on SAN711 in a model of facial neuropathic pain at the 7 th Congress of the European Academy of Neurology (EAN), which is being

PRESS RELEASE May 2 6 , 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the extraordinary shareholders’

PRESS RELEASE May 26 , 2021 Today, on May 2 6, 2021 , the annual shareholders’ meeting was held in Saniona AB . In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual shareholders’ meeting was held only by advance voting (postal vote) in

PRESS RELEASE May 26 , 202 1 Q1 202 1 ( Q1 20 20 ) Revenue was SEK 3.4 M (2.4 M) Operating loss was SEK -94.1 (-27.4 M) Net profit/loss was SEK -83.4 M (43.2 M) Earnings per share were SEK -1.34 (1.47) Diluted earnings per share were SEK -1.34 (1.47) Business highlights in Q 1 2021 The U.S.

PRESS RELEASE May 20 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event , during which it discussed its ion channel drug discovery engine and proprietary IONBASE™ database.